USPTO aims to fend off Fintiv challenge at SCOTUS

Controversial rule precludes a patent review if there is parallel litigation | Big pharma and tech companies insist the rule is “arbitrary and capricious” | US agency backs Vidal’s authority, calling a proposed intervention “unnecessary”.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Americas

Moderna: BioNTech is claiming work ‘it never did’

12 June 2026 In a strong response to BioNTech, Moderna argues its next-gen vaccine is built on a fundamentally different design from the German biotech’s—setting up a scrap over whether a key patent should have been granted.

Americas

US biotech fires trade secrets suit at Chinese pharma group

10 June 2026 Valuable antibody technology, a former employee, and a dispute over patent rights extending across the US, Europe and Asia at the heart of the latest suit.

Americas

Hikma v Amarin: Six takeaways from the pivotal ruling

9 June 2026 A unanimous SCOTUS ruling is being hailed as a major win for Hikma, and for delivering some welcome clarity. Experts tell Marisa Woutersen how its implications could affect pharma patent strategy across the sector.

More features

Moderna: BioNTech is claiming work ‘it never did’

Siemens ordered to recall mammography device across European countries

MoFo bags IP trial duo with 50 years’ combined experience

US biotech fires trade secrets suit at Chinese pharma group

Hikma v Amarin: Six takeaways from the pivotal ruling

Exclusive: ‘When a UPC judge wears their robe, they have no gender’

Clarivate’s new IP president to ‘usher in next phase of growth’

Fed Circ rejects Nexus’ appeal in generics row with biopharma firm

USPTO aims to fend off Fintiv challenge at SCOTUS

More on this story

Editor's picks

Editor's picks

More features